Evidence map›Paper›PMID 39863086›Full record

ArticleMatrix biology : journal of the International Society for Matrix Biology2025

Spatial localization of collagen hydroxylated proline site variation as an ancestral trait in the breast cancer microenvironment.

Harrison Taylor, Laura Spruill, Heather Jensen-Smith, Denys Rujchanarong, Taylor Hulahan, Ashlyn Ivey, Alex Siougiannis, Jennifer R Bethard, Lauren E Ball, George E Sandusky and 8 more

Abstract read
In one paragraph

Article in Matrix biology : journal of the International Society for Matrix Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Harrison TaylorDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
Laura SpruillDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States.
Heather Jensen-SmithEppley Institute for Cancer Research & Allied Diseases, University of Nebraska Medical Center, Omaha, NE, United States.
Denys RujchanarongDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
Taylor HulahanDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
Ashlyn IveyDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
Alex SiougiannisCollege of Medicine, Medical University of South Carolina, Charleston, SC, United States.
Jennifer R BethardDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
Lauren E BallDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
George E SanduskyDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, United States; Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
M A HollingsworthEppley Institute for Cancer Research & Allied Diseases, University of Nebraska Medical Center, Omaha, NE, United States.
Jeremy L BarthDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, United States.
Anand S MehtaDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
Richard R DrakeDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States.
Jeffrey R MarksDepartment of Surgery, Duke Cancer Institute, Duke University, Durham, NC, United States.
Harikrishna NakshatriDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, United States; Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Marvella FordDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, United States.
Peggi M AngelDepartment of Pharmacology & Immunology, Proteomics Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address: angelp@musc.edu.

Funding

South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
SOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20GM103542 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2012 to 2020
$20.2M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
South Carolina Clinical & Translational Research Institute (SCTR)TL1TR001451 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FEGHALI-BOSTWICK, CAROL A. · 2015 to 2024
$4.6M
Collagen Sequence Variants in Racial Disparities of Breast CancerR01CA253460 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2020 to 2024
$2.6M
Bruker scimaX™ Magnetic Resonance Mass SpectrometerS10OD030212 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2021 to 2021
$1.7M
Orbitrap Fusion Lumos ETD Mass SpectrometerS10OD025126 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2018 to 2018
$991k
Orbitrap Mass SpectrometerS10OD010731 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2012 to 2012
$600k
Enzymatic Tools for 2D Tissue Localized and Deeper Proteomic Sequencing of Cancer Stromal ProteinsR21CA240148 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2019 to 2020
$480k
Spatial stromal proteomic biosignatures of DCIS risk and progressionR21CA286287 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2024 to 2024
$380k
BLRD VA I01 BX007249BLRD VA IK6 BX005244Department of Defense W81XWH2010577NCATS NIH HHS TL1 TR001451NCI NIH HHS P30 CA036727NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA253460NCI NIH HHS R21 CA240148NCI NIH HHS R21 CA263464NCI NIH HHS R21 CA286287NCI NIH HHS U01 CA210240NIGMS NIH HHS GM103499NIGMS NIH HHS P20 GM103499NIGMS NIH HHS P20 GM103542NIH HHS 5TL1TR001451NIH HHS P20GM103542NIH HHS P30CA138313NIH HHS R21CA263464NIH HHS S10 OD010731NIH HHS S10OD010731NIH HHS S10 OD025126NIH HHS S10OD025126NIH HHS S10 OD030212
6 · The paper itself

Abstract

Collagen stroma interactions within the extracellular microenvironment of breast tissue play a significant role in breast cancer, including risk, progression, and outcomes. Hydroxylation of proline (HYP) is a common post-translational modification directly linked to breast cancer survival and progression. Changes in HYP status lead to alterations in epithelial cell signaling, extracellular matrix remodeling, and immune cell recruitment. In the present study, we test the hypothesis that the breast cancer microenvironment presents unique PTMs of collagen, which form bioactive domains at these sites that are associated with spatial histopathological characteristics and influence breast epithelial cell signaling. Mass spectrometry imaging proteomics targeting collagens were paired with comprehensive proteomic methods to identify novel breast cancer-related collagen domains based on spatial localization and regulation in 260 breast tissue samples. As ancestry plays a significant role in breast cancer outcomes, these methods were performed on ancestry diverse breast cancer tissues. Lumpectomies from the Cancer Genome Atlas (TCGA; n=10) reported increased levels of prolyl 4-hydroxylase subunit alpha-3 (P4HA3) accompanied by spatial regulation of fibrillar collagen protein sequences. A concise set of triple negative breast cancer lumpectomies (n=10) showed spatial regulation of specific domain sites from collagen alpha-1(I) chain. Tissue microarrays identified proteomic alterations around post-translationally modified collagen sites in healthy breast (n=81) and patient matched normal adjacent (NAT; n=76) and invasive ductal carcinoma (n=83). A collagen alpha-1(I) chain domain encompassing amino acids 506-514 with site-specific proline hydroxylation reported significant alteration between patient matched normal adjacent tissue and invasive breast cancer. Functional testing of domain 506-514 on breast cancer epithelial cells showed proliferation, chemotaxis and cell signaling response dependent on site localization of proline hydroxylation within domain 506-514 variants. These findings support site localized collagen HYP forms novel bioactive domains that are spatially distributed within the breast cancer microenvironment and may play a role in ancestral traits of breast cancer.

Indexed as

Breast NeoplasmsCollagenProlineTumor MicroenvironmentExtracellular MatrixFemaleHumansHydroxylationProtein Processing, Post-TranslationalProteomicsCollagenProlineAncestryBiomarkerBreast cancerCollagenExtracellular matrixHydroxylated prolineImaging mass spectrometryPeptide imagingPeptidesRaceStromaStromal patterns

Identifiers

PMID39863086
PMCPMC13356606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.